SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
3/14/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
5/31/2024 | $11.00 | Overweight | Piper Sandler |
1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
1/5/2024 | Buy → Neutral | Guggenheim | |
12/8/2023 | $7.00 | Buy | Citigroup |
12/8/2023 | Buy | Citigroup |
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
SCHEDULE 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)